Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data (Preprint) DOI
Ponlagrit Kumwichar, Chittawan Poonsiri, Siobhan Botwright

et al.

Published: April 17, 2023

BACKGROUND The durability of heterologous COVID-19 vaccine effectiveness (VE) has been primarily studied in high-income countries, while evaluation policies low- and middle-income countries remains limited. OBJECTIVE We aimed to evaluate the duration during which VE regimens mitigating serious outcomes, specifically severe death following hospitalization with COVID-19, over 50%. METHODS formed a dynamic cohort by linking records Thai citizens aged ≥18 years from citizen vital, vaccine, cases registry databases between May 2021 July 2022. Encrypted identification numbers were used merge data databases. This study focuses on 8 common sequences: CoronaVac/ChAdOx1, ChAdOx1/BNT162b2, CoronaVac/CoronaVac/ChAdOx1, CoronaVac/ChAdOx1/ChAdOx1, CoronaVac/ChAdOx1/BNT162b2, BBIBP-CorV/BBIBP-CorV/BNT162b2, ChAdOx1/ChAdOx1/BNT162b2, ChAdOx1/ChAdOx1/mRNA-1273. Nonimmunized individuals considered for comparisons. was stratified according vaccination status, age, sex, province location, month vaccination, outcome. Data analysis employed logistic regression determine VE, accounting potential confounders time, observed follow-up period 7 months. RESULTS includes 52,580,841 individuals, approximately 17,907,215 17,190,975 receiving 2- 3-dose vaccines (not mutually exclusive), respectively. 2-dose vaccinations offered 50% against 2 months; however, protection significantly declined time. sustained both outcomes at least months, as determined time-interaction modeling. sequence consisting CoronaVac/CoronaVac/ChAdOx1 demonstrated >80% no evidence waning. final monthly measured months after last dose 82% (95% CI 80.3%-84%) 86.3% 83.6%-84%), CONCLUSIONS In Thailand, within 7-month observation period, could not maintain fatal but all did. regimen showed best protective effect COVID-19. estimated across supports adoption prime-boost strategies, primary series inactivated virus boosting either viral vector or an mRNA prevent similar pandemics countries.

Language: Английский

Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022 DOI Open Access
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro

et al.

The Lancet Respiratory Medicine, Journal Year: 2023, Volume and Issue: 11(5), P. 439 - 452

Published: Feb. 11, 2023

Language: Английский

Citations

196
Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis DOI Creative Commons

Shiyao Xu,

Jincheng Li, Hongyuan Wang

et al.

BMC Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: April 27, 2023

Abstract Background The two inactivated SARS-CoV-2 vaccines, CoronaVac and BBIBP-CorV, have been widely used to control the COVID-19 pandemic. influence of multiple factors on vaccine effectiveness (VE) during long-term use against variants is not well understood. Methods We selected published or preprinted articles from PubMed, Embase, Scopus, Web Science, medRxiv, BioRxiv, WHO database by 31 August 2022. included observational studies that assessed VE completed primary series homologous booster infection severe COVID-19. DerSimonian Laird random-effects models calculate pooled estimates conducted meta-regression with an information theoretic approach based Akaike’s Information Criterion select model identify associated VE. Results Fifty-one eligible 151 were included. For prevention infection, study region, variants, time since vaccination; was significantly decreased Omicron compared Alpha ( P = 0.021), 52.8% (95% CI, 43.3 60.7%) Delta 16.4% 9.5 22.8%) Omicron, dose 65.2% 48.3 76.6%) 20.3% 10.5 28.0%) Omicron; after 180 days 0.022). COVID-19, doses, age, design, population type; increased 0.001) primary; though Gamma 0.034), 0.001), Alpha, VEs all above 60% each variant. Conclusions Inactivated protection moderate, 6 months following vaccination, restored vaccination. greatest boosting did decrease over time, sustained for series, more evidence needed assess duration varied most notably Omicron. It necessary ensure vaccination everyone vaccines continue monitoring virus evolution Trial registration PROSPERO, CRD42022353272.

Language: Английский

Citations

16
Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case–Control Study DOI Creative Commons
Natthaprang Nittayasoot, Rapeepong Suphanchaimat, Panithee Thammawijaya

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(12), P. 2123 - 2123

Published: Dec. 12, 2022

Due to the widespread Omicron variant of SARS-CoV-2 in Thailand, effectiveness COVID-19 vaccines has become a major issue. The primary objective this study is examine real-world based on secondary data acquired under normal circumstances setting, protect against treatment with invasive ventilation pneumonia during January April 2022, period when was predominant. We conducted nationwide test-negative case-control study. case and control were matched ratio 1:4 terms age, date specimen collection, hospital collection odds calculated using conditional logistic regression. Overall, there neither distinction between mix-and-match regimens homologous mRNA severe symptoms, nor decline protective effect over period. third fourth dose boosters ChAdOx1 nCoV-19 or provided high levels protection outcomes, approximately 87% 100%, whereas two doses moderate degree (70%). Thus, concludes that current national vaccine strategies provide favourable benefits variant. All Thais should receive at least doses, while high-risk vulnerable groups be administered three doses.

Language: Английский

Citations

22
Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance DOI Creative Commons
Kanchanok Sirison, Natthaprang Nittayasoot,

Ranida Techasuwanna

et al.

Tropical Medicine and Infectious Disease, Journal Year: 2023, Volume and Issue: 8(2), P. 91 - 91

Published: Jan. 30, 2023

The Thai government implemented COVID-19 booster vaccines to prevent morbidity and mortality during the spreading of Omicron variant. However, little is known about which types vaccine should be invested in as dose for population. This study aims investigate most cost-effective a shot empirical evidence policymakers. applied stochastic simulation based on compartmental susceptible-exposed-infectious-recovered model included system dynamics model. We evaluated three scenarios: (1) No booster, (2) A viral vector dose, (3) An mRNA dose. incremental cost-effectiveness ratio (ICER) was calculated provider perspectives. found number cases scenarios with doses lower than non-booster group. Likewise, deaths threefold no-booster scenario. Moreover, estimated grand cost scenario over 100 billion baht, while costs were 70 64.7 respectively. ICER shows that are more Viral appeared slightly terms death aversion. being boosted by an seemed concerning case In conclusion, policies promote shots population either or likely worthwhile both economic public health reasons.

Language: Английский

Citations

12
Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis DOI Creative Commons
Xiaoyin Zhang,

Jiayue Xia,

Lairun Jin

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(2)

Published: June 21, 2023

We aimed to evaluate the effectiveness or efficacy of heterologous homologous COVID-19 vaccine regimens against COVID-19-related outcomes after primary immunization with two doses CoronaVac Sinopharm vaccines. PubMed, EMBASE, Web Science, and Cochrane Library databases were searched up 31 October 2022. The measure was infection booster. results showed booster significantly improved compared immunization. 89.19% (95%CI 78.49, 99.89) for mRNA booster, 87.00% 82.14, 91.85) non-replicating vector 69.99% 52.16, 87.82) 51.48% 41.75, 61.21) inactivated vaccine. Homologous also effective SARS-CoV-2 variants, more evidence is still needed confirm our findings.

Language: Английский

Citations

11
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern DOI Creative Commons
Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 424 - 424

Published: April 17, 2025

Vaccination has been instrumental in curbing the transmission of SARS-CoV-2 and mitigating severity clinical manifestations associated with COVID-19. Numerous COVID-19 vaccines have developed to this effect, including BioNTech-Pfizer Moderna’s mRNA vaccines, as well adenovirus vector-based such Oxford–AstraZeneca. However, emergence new variants subvariants SARS-CoV-2, characterized by enhanced transmissibility immune evasion, poses significant challenges efficacy current vaccination strategies. In review, we aim comprehensively outline landscape emerging concern (VOCs) sub-lineages that recently surfaced post-pandemic years. We assess effectiveness existing their booster doses, against these subvariants, BA.2-derived sub-lineages, XBB BA.2.86 (Pirola). Furthermore, discuss latest advancements vaccine technology, multivalent pan-coronavirus approaches, along development several next-generation coronavirus exosome-based, virus-like particle (VLP), mucosal, nanomaterial-based vaccines. Finally, highlight key critical areas for future research address evolving threat develop strategies combating viral threats, thereby improving preparedness pandemics.

Language: Английский

Citations

0
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants DOI Creative Commons
Suvimol Niyomnaitham, Anan Jongkaewwattana, Atibordee Meesing

et al.

International Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 129, P. 19 - 31

Published: Jan. 20, 2023

The study aimed to compare the immunogenicity and safety of fractional (half) third doses heterologous COVID-19 vaccines (AZD1222 or BNT162b2) full after two-dose CoronaVac when boosting three different extended intervals.

Language: Английский

Citations

10
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial DOI Creative Commons
Sant Muangnoicharoen,

Rakpong Wiangcharoen,

Sira Nanthapisal

et al.

Vaccine, Journal Year: 2023, Volume and Issue: 41(32), P. 4648 - 4657

Published: June 15, 2023

The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been extensively used worldwide. Heterologous boosting after primary vaccination can induce higher immune responses against SARS-CoV-2 than homologous boosting. safety and immunogenicity 28 days of a single Ad26.COV2.S booster dose given at different intervals 2 doses are presented.

Language: Английский

Citations

8
Learning from pandemic responses: Informing a resilient and equitable health system recovery in Thailand DOI Creative Commons
Viroj Tangcharoensathien,

Jos Vandelaer,

Richard J. C. Brown

et al.

Frontiers in Public Health, Journal Year: 2023, Volume and Issue: 11

Published: Jan. 25, 2023

This article is part of the Research Topic ‘ Health Systems Recovery in Context COVID-19 and Protracted Conflict ’. The third quarter 2022 saw cases deaths Thailand reduced significantly, high levels vaccine coverage. was declared an “endemic” disease, economic activities resumed. paper reviews pre-pandemic health systems capacity identifies pandemic response strengths, weaknesses lessons that guided resilient equitable system recovery. Robust adaptive strategies drive effective response. To support recovery should (1) minimize vulnerability extend universal coverage to include migrant workers dependents; (2) sustain provincial primary healthcare (PHC) strengthen PHC greater Bangkok; (3) leverage information technology for telemedicine teleconsultation; (4) enhance case event-based surveillance notifiable diseases, public threats, including pathogens with potential wildlife domesticated animals. requires policy financial commitment across successive governments, adequate numbers committed competent workforce at all supported by over a million village volunteers, strong social capital community resilience. A strengthened global architecture international collaboration also have critical roles establishing local capacities develop manufacture products through transfer know-how. Countries engage ongoing Inter-government Negotiating Body ensure legally binding instrument safeguard world from catastrophic impacts future pandemics.

Language: Английский

Citations

7
Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study DOI Creative Commons

Dingmei Zhang,

Jiayi Zhong, Husheng Xiong

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 566 - 566

Published: March 1, 2023

This study aims to explore the relationship between doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in real-world setting, so as preliminarily evaluate protective effect induced by vaccination. We conducted a test-negative case-control recruited test-positive cases controls outbreak caused BA.2 April 2022 Guangzhou, China. All participants were 3 years older. The vaccination status case group control was compared vaccinated all participants, respectively, estimate immune protection vaccines. After adjusting for sex age, with mere single dose, full (OR = 0.191, 95% CI: 0.050 0.727) booster 0.091, 0.011 had more superior effect. Compared one second dose effective males 0.090), well two 0.089) three 0.090) among individuals aged 18-59. Whereas, when unvaccinated, 7.715, 1.904 31.254) 2.055, 1.162 3.635) could contribute increased risk after age. Meanwhile, contrast unvaccinated individuals, result also manifested first 12.400) 21.500), 1.890), 1.945) people In conclusion, exceeded incomplete vaccination, which effective. Nevertheless, may increase people. from transmission traits BA.2, particularity stronger awareness population, ADE decrease antibody titers long time It is crucial this issue depth formulation future strategies.

Language: Английский

Citations

7